ASTRAZENECA'S first quarter profit was hit by generic competition to cholesterol fighter Crestor and higher costs, but the drugmaker expects a better second half and said it remained on track...

THE concept of combining two immunotherapy drugs to fight lung cancer - not so long ago one of the hottest ideas in cancer research - has suffered a fresh blow from the failure of an AstraZeneca...

[LONDON] The concept of combining two immunotherapy drugs to fight lung cancer - not so long ago one of the hottest ideas in cancer research - has suffered a fresh blow from the failure of an...

ASTRAZENECA is spinning off six early-stage experimental drugs into a new US$250 million stand-alone biotech company focused on severe autoimmune diseases.